No Data
Yimingangke (01541) soared by 37% in the Hong Kong Stock Connect program, signing an authorization and cooperation agreement with SynBioTx.
In the morning, the stock price of Yimingang Holdings (01541) rose against the trend. At the time of publication, it was reported to be HKD 19.82, an increase of 37.64%, with a turnover of HKD 9.0619 million. On the news side, it has entered into an authorization and cooperation agreement with SynBioTx, and the company agrees to grant SynBioTx the exclusive authorization to research, develop and commercialize several targeted programmed cell death ligand 1 and vascular endothelial growth factor bispecific antibodies, as well as several targeted monoclonal antibodies against T lymphocyte-related protein 4 for use outside Greater China. According to the agreement, the company will receive no more than USD 50 million.
Hong Kong stocks surge | Amgen-B (01541) opens more than 11%, reaches authorization cooperation on two innovative cancer drugs, with a total amount over 2 billion US dollars.
Yimingang-K (01541) opened more than 11%, as of press time, up 11.11%, reported HKD 16, turnover of 0.4416 million Hong Kong dollars.
Yimingangke-B (01541) has entered into an authorization and cooperation agreement with SynBioTx Inc.
Emin Bio-B (01541) announced that on August 1, 2024, the company entered into an agreement with SynBioTx I...
Express News | ImmuneOnco Biopharmaceuticals Shanghai Inc - Under Deal, Co to Receive Upfront & Potential Near-Term Payments of up to $50 Mln
Express News | ImmuneOnco Biopharmaceuticals Shanghai - License and Collaboration Agreement With Synbiotx for Imm2510 and Imm27M
Express News | Instil Bio Inc - ImmuneOnco to Receive Royalties on Global Ex-China Sales
No Data
